Psoriasis patients generate increased serum levels of autoantibodies to tumor necrosis factor-α and interferon-α
Introduction
Psoriasis is a chronic, immunologically based inflammatory skin disease in which cytokines and chemokines released from cutaneous antigen-presenting cells, T cells and keratinocytes are believed to play a key role [1], [2]. Biological treatments that target cytokines such as tumor necrosis factor-α (TNF-α) and interleukin (IL) 12/23 have shown effectiveness in controlling psoriasis [3], [4].
We have previously shown in experimental animal models that during different experimental autoimmune conditions, the immune system generates a beneficial autoantibody (auto Ab) response to a limited number of inflammatory mediators that drive the pathogenesis of each disease [5], [6], [7], [8], [9], [10], [11], [12], [13]. One of these studies which has been extended to human rheumatoid arthritis (RA) [11] showed that subjects with active RA, but not osteoarthritis (OA) develop a selective auto Ab response to TNF-α, but not to many other cytokines, even though they are expressed at the autoimmune site. Anti-TNF-α therapy is highly effective for RA, but not OA [14]. We sought to detect auto Abs against several pro-inflammatory cytokines and chemokines, most of which are believed to participate in psoriasis. Our results show for the first time that psoriasis patients produce highly significant increased levels of auto Abs against two of the key players in the pathogenesis of psoriasis: TNF-α and interferon-α (IFN-α) [2], and that these auto Abs demonstrate some neutralizing activity in vitro.
Section snippets
Study design and serum samples
The present study was conducted in accordance with the declaration of Helsinki (Institutional Review Board certification No 2577). Sera were collected from 37 patients with psoriasis vulgaris prior to phototherapy: 25 males and 12 females, aged 20–76 years (yrs), median 43.5 yrs; 18 patients with atopic dermatitis (AD): 10 males and 8 females, aged 19–69 yrs, median 30 yrs; and 56 healthy subjects (36 males and 20 females; aged 27–62 yrs, median 45.5 years). The psoriasis area and severity
Auto Abs to the cytokines and chemokines
Highly significant increased titers of auto Abs to TNF-α and IFN-α, but not to CCL2, CCL3 and CCL5 were detected in the sera of the psoriasis patients compared with the healthy subjects (p < 0.0001) and AD patients (p = 0.002 and 0.0004, respectively) (Fig. 1, Fig. 2). The mean titers of these two auto Abs in the psoriasis group were more than fourfold the mean titers in the other two groups (Fig. 1, Fig. 2). The serum titers of IL-17 of the psoriasis patients were borderline significantly
Discussion
The present study demonstrated that psoriasis patients generate markedly increased serum levels of auto Abs against TNF-α and IFN-α compared to AD patients and healthy subjects, and that these auto Abs demonstrate some neutralizing activity in vitro. Significantly increased levels of anti-TNF-α auto Abs have been recently demonstrated by our group in patients suffering from RA compared with patients with OA and healthy controls [11]. Furthermore, TNF-α specific auto Abs produced in rats with
References (44)
- et al.
Beneficial autoimmunity to proinflammatory mediators restrains the consequences of self-destructive immunity
Immunity
(2003) - et al.
Costimulation of T cells for tumor immunity
Immunol Today
(1993) - et al.
Increased sensitivity to interferon-α in psoriatic T-cells
J Invest Dermatol
(2005) - et al.
Current and future management of psoriasis
Lancet
(2007) - et al.
Characterization of FcέR1-bearing CD123+ blood dendritic all antigen-2+ plasmacytoid dendritic cells in atopic dermatitis
J Allergy Clin Immunol
(2004) - et al.
Production of Il-4, IL-2, IFN-gamma, and TNF-alpha by peripheral blood mononuclear cells of patients with atopic dermatitis
J Dermatol Sci
(1992) - et al.
Infliximab in the treatment of moderate to severe atopic dermatitis
J Am Acad Dermatol
(2005) - et al.
Keratinocytes from patients with atopic dermatitis and psoriasis show a distinct chemokine production profile in response to T-cell derived cytokines
J Allergy Clin Immunol
(2001) - et al.
Pathogenesis and therapy of psoriasis
Nature
(2007) - et al.
Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities
J Clin Invest
(2004)
Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial
Lancet
A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis
N Engl J Med
Long-lasting protective immunity to experimental autoimmune encephalomyelitis following vaccination with naked DNA encoding C–C chemokines
J Immunol
Augmentation of natural immunity to a pro-inflammatory cytokine (TNF-alpha) by targeted DNA vaccine confers long-lasting resistance to experimental autoimmune encephalomyelitis
Gene Ther
A targeted DNA vaccine augments the natural immune response to self TNF-alpha and suppresses ongoing adjuvant arthritis
J Immunol
C–C chemokine-encoding DNA vaccines enhance breakdown of tolerance to their gene products and treat ongoing adjuvant arthritis
J Clin Invest
Targeting the function of IFN-gamma-inducible protein 10 suppresses ongoing adjuvant arthritis
J Immunol
Plasmid DNA encoding IFN-gamma-inducible protein 10 redirects antigen-specific T cell polarization and suppresses experimental autoimmune encephalomyelitis
J Immunol
Suppression of ongoing adjuvant-induced arthritis by neutralizing the function of the p28 subunit of IL-27
J Immunol
Beneficial autoimmunity participates in the regulation of rheumatoid arthritis
Front Biosci
Role of cytokines in rheumatoid arthritis
Ann Rev Immunol
Diagnostic features of atopic dermatitis
Acta Derm Venereol Suppl (Stockh)
Cited by (15)
Autoantibodies in psoriatic disease
2023, Advances in Clinical ChemistryAnti-cytokine autoantibodies: mechanistic insights and disease associations
2024, Nature Reviews ImmunologyInterferon autoantibodies as signals of a sick thymus
2024, Frontiers in ImmunologyAutoantibodies targeting type I interferons: Prevalence, mechanisms of induction, and association with viral disease susceptibility
2023, European Journal of ImmunologyThe chemokine landscape: one system multiple shades
2023, Frontiers in Immunology